• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Civica Rx Adds Anthem and Calalent As Partners, Names Its Retail Arm CivicaScript

Article

Former OptumRx executive, Gina Guinasso, J.D., is president of the newly named retail venture.

Civica Rx, founded in 2018 as a nonprofit supplier of generic drugs to hospitals, announced today that it was expanding its fledging retail generics business to include a partnership with Anthem and has officially named the retail subsidiary CivicaScript.

Gina Guinasso

Gina Guinasso

The company also announced that Gina Guinasso, J.D., has been named president of CivicaScript. Prior to CivicaScript, Guinasso had been senior vice president of commercial and Medicare formulary strategy for OptumRx, the UnitedHealth Group’s PBM. Her LinkedIn page says she started at CivicaScript in May.

This morning’s press release also announced that Civica Rx has entered into a long-term partnership with Catalent, a drug development and manufacturing company headquartered in Somerset, New Jersey.

Civica announced last year that it was branching out from its hospital business into the retail market in partnership with the Blue Cross Blue Shield Foundation and 17 Blues plans. But today's news elevates the profile of the subsidiary and may foreshadow it becoming a disruptive force in the generics market. With the addition of Anthem, the CivicaScript subsidiary will have insurance partners that cover about 100 million lives.

The press release says that CivicaScript will start by developing and manufacturing six to 10 common, high-priced generics and that they will be available as early as 2022 through retail and mail-order pharmacies. “Using a cost-plus and price transparent model, CivicaScript … plans to innovate and further transform the supply chain to lower the cost of prescription medicines,” the press release says..

The announcement says all of Civica Rx’s hospital system members will have access to the retail medications manufactured by the newly named subsidiary. More than 50 hospital systems that comprise 1,400 hospitals are Civica Rx members.

Catalent will develop a range of CivicaScript-owned generic Abbreviated New Drug Applications, according to he press release, and production will take place at the company’s facilities in Somerset and in Winchester, Kentucky.

“We are delighted to welcome our newest partners and our new CivicaScript president, Gina Guinasso, a nationally revered managed healthcare executive,” Martin VanTrieste, Civica Rx’s president and CEO, said in the press release.

Civica Rx was a founded by seven health systems (CommonSpirit Health, HCA Healthcare, Intermountain Healthcare, Mayo Clinic, Providence St. Joseph Health, SSM Health and Trinity Health) and three philanthropies (the Laura and John Arnold Foundation, the Peterson Center on Healthcare and the Gary and Mary West Foundation). Kaiser Permanente and Memorial Hermann Health have since joined these organizations on its board of directors.

Related Videos
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
Video 3 - "Harnessing Prescription Drug Therapeutics as Monotherapy and Adjunct Therapy"
Video 8 - "Demographic Differences That Impact Care"
Related Content
© 2024 MJH Life Sciences

All rights reserved.